CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities
暂无分享,去创建一个
H. Beltran | S. Terry | Y. Allory | D. Salomon | A. De la taille | P. Maillé | A. Londoño-Vallejo | F. Vacherot | D. Destouches | F. Semprez | G. Ploussard | C. Pimpie | N. Nicolaiew | Ihsan Y. El-Sayed
[1] Yi-Song Wang,et al. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. , 2014, The Journal of clinical investigation.
[2] L. Norton,et al. N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties , 2014, Oncogene.
[3] C. Porta,et al. Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..
[4] H. Beltran,et al. The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression , 2014, Front. Oncol..
[5] M. Nieto. Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells , 2013, Science.
[6] Jixiang Ding,et al. Cripto is required for mesoderm and endoderm cell allocation during mouse gastrulation. , 2013, Developmental biology.
[7] Yan Li,et al. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. , 2013, The international journal of biochemistry & cell biology.
[8] M. Hendrix,et al. The significance of a Cripto-1-positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics , 2013, Cell cycle.
[9] Fabrice Andre,et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. , 2013, Cancer discovery.
[10] C. Dinney,et al. Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting , 2013, PloS one.
[11] Jing Yang,et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.
[12] W. Vale,et al. Cripto/GRP78 modulation of the TGF‐β pathway in development and oncogenesis , 2012, FEBS letters.
[13] M. Knowles,et al. FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms , 2012, PloS one.
[14] C. Bianco,et al. Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. , 2012, The American journal of pathology.
[15] Biplab Bose,et al. Human recombinant Cripto-1 increases doubling time and reduces proliferation of HeLa cells independent of pro-proliferation pathways. , 2012, Cancer letters.
[16] John T. Wei,et al. Beyond PSA: The Next Generation of Prostate Cancer Biomarkers , 2012, Science Translational Medicine.
[17] A. Postigo,et al. β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness , 2011, Proceedings of the National Academy of Sciences.
[18] Manuel Hidalgo,et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. , 2011, Cell stem cell.
[19] Robert A. Weinberg,et al. Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.
[20] M. Hendrix,et al. Expression and functional role of CRIPTO-1 in cutaneous melanoma , 2011, British Journal of Cancer.
[21] M. Hendrix,et al. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells , 2011, The Prostate.
[22] M. Henry,et al. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? , 2011, Nature Reviews Urology.
[23] J. Shen,et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation , 2011, Oncogene.
[24] Carlos L. Arteaga,et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.
[25] Sarat Chandarlapaty,et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.
[26] O. Kallioniemi,et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. , 2010, Cancer research.
[27] Maria Cristina Rangel,et al. Role of Cripto-1 in stem cell maintenance and malignant progression. , 2010, The American journal of pathology.
[28] M. Hendrix,et al. Cripto‐1 Is a Cell Surface Marker for a Tumorigenic, Undifferentiated Subpopulation in Human Embryonal Carcinoma Cells , 2010, Stem cells.
[29] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[30] R. Huang,et al. Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.
[31] C. Bianco,et al. Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1 , 2009, The Journal of cell biology.
[32] J. C. Belmonte,et al. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways , 2009, Oncogene.
[33] M. Klymkowsky,et al. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. , 2009, The American journal of pathology.
[34] J. Trosko,et al. Profiling Cancer Stem Cells in Androgen‐Responsive and Refractory Human Prostate Tumor Cell Lines , 2009, Annals of the New York Academy of Sciences.
[35] D. Constam,et al. Cripto Localizes Nodal at the Limiting Membrane of Early Endosomes , 2008, Science Signaling.
[36] D. Constam,et al. Cripto recruits Furin and PACE4 and controls Nodal trafficking during proteolytic maturation , 2008, The EMBO journal.
[37] D. Brewer,et al. Expression profiling of CD133+ and CD133— epithelial cells from human prostate , 2008, The Prostate.
[38] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[39] A-P Lu,et al. Positive association of up‐regulated Cripto‐1 and down‐regulated E‐cadherin with tumour progression and poor prognosis in gastric cancer , 2008, Histopathology.
[40] Leif E. Peterson,et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. , 2007, Cancer cell.
[41] W. Fischer,et al. GRP78 and Cripto Form a Complex at the Cell Surface and Collaborate To Inhibit Transforming Growth Factor β Signaling and Enhance Cell Growth , 2007, Molecular and Cellular Biology.
[42] C. Kennedy,et al. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[43] S. Tabibzadeh,et al. Lefty at the Crossroads of “Stemness” and Differentiative Events , 2006, Stem cells.
[44] G. D'aiuto,et al. Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer , 2006, Clinical Cancer Research.
[45] J. Foidart,et al. Regulation of vimentin by SIP1 in human epithelial breast tumor cells , 2006, Oncogene.
[46] P. Karakiewicz,et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. , 2006, The Journal of urology.
[47] M. Hendrix,et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness , 2006, Nature Medicine.
[48] A. Ebert,et al. Role of human cripto-1 in tumor angiogenesis. , 2005, Journal of the National Cancer Institute.
[49] N. Normanno,et al. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV‐Cripto‐1 transgenic mice , 2004, Journal of cellular physiology.
[50] N. Normanno,et al. CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. , 2004, International journal of oncology.
[51] S. Ramaswamy,et al. Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.
[52] N. Normanno,et al. Cripto‐1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF‐7 breast cancer cells , 2004, Journal of cellular physiology.
[53] Chenbei Chang,et al. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto. , 2003, Genes & development.
[54] E. Adamson,et al. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells , 2003, The Journal of cell biology.
[55] D. Kane,et al. One-eyed pinhead regulates cell motility independent of Squint/Cyclops signaling. , 2003, Developmental biology.
[56] N. Normanno,et al. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. , 2003, Cancer research.
[57] F. Rosa. Cripto, a Multifunctional Partner in Signaling: Molecular Forms and Activities , 2002, Science's STKE.
[58] A. Ebert,et al. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. , 2001, Experimental cell research.
[59] A. Ebert,et al. Cripto-1 induces apoptosis in HC-11 mouse mammary epithelial cells , 2000, Cell Death and Differentiation.
[60] S. Schwartz,et al. A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.
[61] A. Ebert,et al. Cripto-1 Indirectly Stimulates the Tyrosine Phosphorylation oferb B-4 through a Novel Receptor* , 1999, The Journal of Biological Chemistry.
[62] A. Wynshaw-Boris,et al. Cripto is required for correct orientation of the anterior–posterior axis in the mouse embryo , 1998, Nature.
[63] M. Kirschner,et al. The identification of two novel ligands of the fgf receptor by a yeast screening method and their activity in xenopus development , 1995, Cell.
[64] S. Schwartz,et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.
[65] A. Simeone,et al. The murine cripto gene: expression during mesoderm induction and early heart morphogenesis. , 1993, Development.
[66] Silvana,et al. Molecular characterization of a gene of the ‘EGF family’ expressed in undifferentiated human NTERA2 teratocarcinoma cells. , 1989, The EMBO journal.
[67] G. Murphy,et al. LNCaP model of human prostatic carcinoma. , 1983, Cancer research.
[68] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[69] Francesca Demichelis,et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. , 2011, Genome research.
[70] N. Normanno,et al. Cripto-1: an oncofetal gene with many faces. , 2005, Current topics in developmental biology.
[71] Frank McCormick,et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. , 2004, Genes & development.
[72] E. Okajima,et al. Cripto expression in human urological tumors. , 1997, Cancer letters.